Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

September 30, 2028

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

SOX plus PD-1 inhibitor

SOX or XELOX plus PD-1 inhibitor

DRUG

SOX Chemotherapy

SOX or XELOX

All Listed Sponsors

lead

Liaoning Cancer Hospital & Institute

OTHER